Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 3,696,000 $ 22,676,000
Investments in debt securities 5,929,000 10,845,000
Accounts receivable - trade 970,000 1,000,000
Settlement receivable - current portion 5,100,000 5,100,000
Convertible promissory note receivable and accrued interest 1,669,000  
Prepaid expenses and other current assets 414,000 1,549,000
Current assets held for sale 20,457,000 3,900,000
Total Current Assets 38,235,000 45,070,000
Restricted cash 253,000 5,996,000
Convertible promissory note receivable and accrued interest   1,631,000
Finance lease right-of-use assets, net of accumulated amortization 746,000  
Operating lease right-of-use asset 2,873,000 3,068,000
Fixed assets, net of accumulated depreciation 4,245,000 1,373,000
Intangible assets, net of accumulated amortization 5,398,000 4,851,000
Security deposits 50,000 29,000
Prepaid expenses - noncurrent   74,000
Noncurrent assets held for sale   37,314,000
Total Assets 51,800,000 99,406,000
Current liabilities:    
Accounts payable 4,002,000 4,264,000
Accrued expenses 5,001,000 3,764,000
Finance lease obligations - current portion 259,000  
Operating lease obligation - current portion 315,000 91,000
Equipment financing payable - current portion 152,000  
Term note payable - net of deferred financing costs 16,011,000 22,161,000
Contract liabilities 88,000 100,000
Current liabilities related to assets held for sale 1,947,000 56,000
Total Current Liabilities 27,775,000 30,436,000
Finance lease obligations - net of current portion 490,000  
Operating lease obligation - net of current portion 3,324,000 3,514,000
Equipment financing payable - net of current portion 323,000  
Accrued expenses - noncurrent 1,065,000  
Noncurrent liabilities related to assets held for sale   1,971,000
Total Liabilities 32,977,000 35,921,000
iBio, Inc. Stockholders' Equity:    
Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively
Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2022 and June 30, 2022; 12,368,287 and 8,727,158 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively 12,000 9,000
Additional paid-in capital 294,591,000 287,619,000
Accumulated other comprehensive loss (167,000) (213,000)
Accumulated deficit (275,613,000) (223,930,000)
Total iBio, Inc. Stockholders' Equity 18,823,000 63,485,000
Total Liabilities and Equity $ 51,800,000 $ 99,406,000